Abstract
There is a trend towards greater use of pharmacoeconomics and outcomes research in Europe indicating that health economic researchers in the European Union (EU) are not wasting their time, assured Professor Michael Drummond at the inaugural European conference of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) [Cologne, Germany; December 1998]. However, other than in centralised drug pricing and reim bursement discussions, he believes that the use of pharmacoeconomic evaluation in Europe is still limited. Furthermore, the great diversity in the healthcare systems of Europe makes it difficult to foresee harmonisation of drug pricing and reimbursement decisions at least in the short term.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
